Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL

Urology

Volumn 76, Issue 4, 2010, Pages 919-922

  Kim, Hong Seok ^a   Jeon, Seong Soo ^a   Choi, Jae Duck ^a   Kim, Wansuk ^a   Han, Deok Hyun ^a   Jeong, Byong Chang ^a   Seo, Seong Il ^a   Lee, Kyu Sung ^a   Lee, Sung Won ^a   Lee, Hyun Moo ^a   Choi, Han Yong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; ETHNIC GROUPS; HUMANS; KOREA; MALE; MIDDLE AGED; ORGAN SIZE; PALPATION; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77957746321     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.12.036     Document Type: Article

References (19)

1. P.J. Littrup, R.A. Kane, and C.J. Mettlin Cost-effective prostate cancer detection Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection project Cancer 74 1994 3146 3158
2. W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination Enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
3. F.H. Schroder, I. van der Cruijsen-Koeter, and H.J. de Koning Prostate cancer detection at low prostate specific antigen J Urol 163 2000 806 812
4. D.S. Smith, G.F. Carvalhal, and D.E. Mager Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men J Urol 160 1998 1734 1738
5. R.J. Babaian, H. Fritsche, and A. Ayala Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL Urology 56 2000 1000 1006
6. T. Kobayashi, K. Nishizawa, and K. Ogura Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population Urology 63 2004 727 731
7. H.K. Park, S.K. Hong, and S.S. Byun T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population Urology 68 2006 85 88
8. R.W. Allan, H. Sanderson, and J.I. Epaein Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density J Urol 170 2003 370 372
9. F. Labrie, B. Candas, and L. Cusan Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial Prostate 59 2004 311 318
10. P. Pepe, P. Panella, and L. D'Arrigo Should men with serum prostate-specific antigen < or = 4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review Oncology 70 2006 81 89
11. J.S. Krumholtz, G.F. Carvalhal, and C.G. Ramos Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469 473 discussion 473-464
12. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
13. R.P. Smith, S.B. Malkowicz, and R. Whittington Identification of clinically significant prostate cancer by prostate-specific antigen screening Arch Intern Med 164 2004 1227 1230
14. J. Hugosson, G. Aus, and H. Lilja Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma Cancer 100 2004 1397 1405
15. M.H. Sokoloff, X.J. Yang, and M. Fumo Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL BJU Int 93 2004 499 502
16. C.L. Foley, S.R. Bott, and K. Thomas A large prostate at radical retropubic prostatectomy does not adversely affect cancer control, continence or potency rates BJU Int 92 2003 370 374
17. H. Augustin, P.G. Hammerer, and M. Graefen Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction Eur Urol 43 2003 455 460
18. S.E. Lerner, T.M. Seay, and M.L. Blute Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis J Urol 155 1996 821 826
19. M. Noguchi, T.A. Stamey, and J.E. McNeal Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer J Urol 166 2001 104 109 discussion 109-110